Refills Health: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.refills.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.

1. 1

   “The compounded semaglutide products displayed on your website identify “Refills Health” on the pictured label, suggesting Refills Health is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide products appear on your website: “clinically proven””

3. 3

   ““the same active ingredient found in certain FDA approved treatments””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

refills.com returned a live storefront when we checked in August 2026, with personalised GLP-1 and GIP+GLP-1 products alongside intimacy, hair-growth and daily-health lines. We did not review every page on the site.

The word "certain" is the tell, and it is worth understanding why it did not help. Adding a qualifier makes a sentence more accurate about the brands being referenced while leaving untouched the thing FDA cared about: what the reader concludes about the vial being sold. That is the general shape of these letters — the agency is not grading the sentence for technical truth, it is asking what an ordinary shopper takes away. Nothing here concerns price, and nothing concerns whether the medication works. So the practical use of this letter is narrow. It tells you that careful wording on a product page is not the same as a regulatory credential, and that when you are comparing this company's number against a brand's, you are comparing a compounded product against an approved one regardless of how precisely the page is written.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Refills Health failed to respond.